Andresen Viola, Layer Peter
Israelitic Hospital, University of Hamburg, Hamburg, Germany.
Visc Med. 2018 Apr;34(2):123-127. doi: 10.1159/000488695. Epub 2018 Apr 12.
Chronic constipation is a very common medical problem with relevant impact on the patients' quality of life. Modern definitions recognize constipation as a polysymptomatic disorder, including various aspects of disturbed defecation. Current guidelines recommend a stepwise approach in the management of chronic constipation. Isolated or concomitant evacuation disorders should be identified and may need differential/additional treatment. Baseline measures include lifestyle components and bulking agents. The next step recommends treatment with conventional laxatives. In refractory patients, modern medical therapies, such as the prokinetic prucalopride or the secretagogues linalotide or lubiprostone, may be used effectively. For patients with opioid-induced constipation, the modern concept of peripherally acting µ-opioid antagonists has shown to successfully improve this increasing medical problem and even to potentially increase survival time in terminally ill patients on opioid therapy. Prolonged-released oral naloxone (in fixed combination with oxycodone), oral naloxegol or naldemedine, and subcutaneous methylnaltrexone have all demonstrated good efficacy and tolerability in the treatment of opioid-induced constipation. To adequately apply stepwise treatment algorithms, a simple tool to identify treatment failure may improve patient care.
慢性便秘是一个非常常见的医学问题,对患者的生活质量有相关影响。现代定义将便秘视为一种多症状疾病,包括排便紊乱的各个方面。当前指南推荐在慢性便秘的管理中采用逐步治疗方法。应识别孤立或伴随的排便障碍,可能需要进行鉴别/额外治疗。基线措施包括生活方式因素和容积性泻药。下一步推荐使用传统泻药进行治疗。对于难治性患者,现代医学疗法,如促动力药普芦卡必利或促分泌剂利那洛肽或鲁比前列酮,可能会有效使用。对于阿片类药物引起的便秘患者,外周作用的μ-阿片受体拮抗剂的现代概念已显示能成功改善这一日益增加的医学问题,甚至可能延长接受阿片类药物治疗的晚期患者的生存时间。缓释口服纳洛酮(与羟考酮固定组合)、口服纳洛西醇或纳地美定以及皮下注射甲基纳曲酮在治疗阿片类药物引起的便秘方面均已显示出良好的疗效和耐受性。为了充分应用逐步治疗算法,一个识别治疗失败的简单工具可能会改善患者护理。